Spoonful of Sugar Spoonful of Sugar (SoS) is a unique and diverse team of specialists in illness and medicines-related behaviour, hand-picked from academic, healthcare, communications, creative and ...

PharmaNet/i3, a leader in drug development services, has a global infrastructure, therapeutic expertise, and commitment to quality that is unmatched in the industry. For pharmaceutical, biotechnology, ...

AstraZeneca’s Fasenra (benralizumab) has been approved by the European Commission (EC) to treat eosinophilic granulomatosis ...

Novo Nordisk has shared promising results from a late-stage study of semaglutide in patients with metabolic ...

LEO Pharma has shared final results from a long-term extension study of its atopic dermatitis (AD) drug Adbry ...

The launch of a new pharmaceutical product depends on a host of determinants and it just takes one factor to send the launch ...

Knowing this, it amazes me how many pharmaceutical organisations of all sizes are missing the mark on key areas of launch ...

Novartis’ Scemblix (asciminib) has been granted accelerated approval by the US Food and Drug Administration (FDA) to treat a new subset of chronic myeloid leukaemia (CML) patients. The STAMP inhibitor ...

Dermavant Sciences has shared positive long-term results for its plaque psoriasis-approved Vtama (tapinarof) cream in adults and children as young as two years old with atopic dermatitis (AD).

Around 86% of clinical trials do not meet patient recruitment goals, ultimately failing to improve patient outcomes and resulting in financial losses for sponsors and research sites (Rangu and Maxwell ...

This blog will discuss some important aspects to consider to maximise patient retention on your flu clinical trials. For more information on patient recruitment considerations, check out our previous ...